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Abstract
Background: Multiple comorbidity measures have been developed for risk-adjustment in studies using
administrative data, but it is unclear which measure is optimal for specific outcomes and if the measures are
equally valid in different populations. This research examined the predictive performance of five comorbidity
measures in three population-based cohorts.
Methods: Administrative data from the province of Saskatchewan, Canada, were used to create the cohorts. The
general population cohort included all Saskatchewan residents 20+ years, the diabetes cohort included individuals
20+ years with a diabetes diagnosis in hospital and/or physician data, and the osteoporosis cohort included
individuals 50+ years with diagnosed or treated osteoporosis. Five comorbidity measures based on health services
utilization, number of different diagnoses, and prescription drugs over one year were defined. Predictive
performance was assessed for death and hospitalization outcomes using measures of discrimination (c-statistic) and
calibration (Brier score) for multiple logistic regression models.
Results: The comorbidity measures with optimal performance were the same in the general population (n =
662,423), diabetes (n = 41,925), and osteoporosis (n = 28,068) cohorts. For mortality, the Elixhauser index resulted in
the highest c-statistic and lowest Brier score, followed by the Charlson index. For hospitalization, the number of
diagnoses had the best predictive performance. Consistent results were obtained when we restricted attention to
the population 65+ years in each cohort.
Conclusions: The optimal comorbidity measure depends on the health outcome and not on the disease
characteristics of the study population.
Background
Population-based administrative databases are com-
monly used in studies about health status and health
service utilization. These databases enable easy access to
demographic and health-related data on large study
populations but they are not without limitations. Studies
that use administrative data employ observational
designs, which can result in differences amongst study
groups, which may also be related to the outcome of
interest. This may lead to spurious results if these differ-
ences are not controlled using appropriate risk-adjust-
ment methodologies. One of the most important
predictors of health-related outcomes is the presence of
comorbidities, or pre-existing health conditions that
coexist with an index disease [1]. Therefore, for all
research related to health-related events and services, it
is essential to risk-adjust for comorbidity in order to get
unbiased estimates.
A number of comorbidity measures have been applied to
administrative data. Some are simple, such as counts of
the number of physician visits, diagnoses, or prescription
drug dispensations within a prescribed time frame [2].
Comorbidity indices based on specific sets of diagnoses for
chronic conditions or prescription drugs used to treat
chronic conditions have also been developed. The Chronic
Disease Score (CDS) is a weighted index of the burden of
comorbid conditions based upon pharmaceutical data
from administrative databases [3]. Diagnosis-related
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any medium, provided the original work is properly cited.indices include the Charlson and Elixhauser indices, which
use International Classification of Disease (ICD) diagnosis
codes to identify major health problems, such as heart or
lung disease [4,5]. Both the Charlson and Elixhauser
indices were originally developed using in-hospital popula-
tions to predict mortality, although they have been applied
to outpatient populations [6-8]. All of these measures are
potentially useful for comparing different populations
because they are general measures of comorbidity.
Previous research has focused on the performance of
these comorbidity measures in either specific popula-
tions or for specific outcomes, but never in multiple
populations for multiple outcomes. The majority of
research has focused on in-patient populations [9-11]
and chronic disease populations, including osteoarthritis
[6], hypertension [12], and migraine [13]. Most of these
studies investigate death or health care costs as the out-
come and results have been inconsistent, likely as the
result of differences between studies in data sources and
how both comorbidity measures and outcomes are
defined. More limited research has been conducted in
general populations and the research that has been done
has focused on mortality as the primary health outcome
measure [7,14]. Fewer have investigated health service
utilization outcome measures [7,15]. Overall, the major-
ity of studies focus on a single population or outcome
and the consistency of the findings across populations
and outcomes bears further investigation. With this in
mind, we investigated the performance of five comorbid-
ity measures for predicting death and health services
utilization outcomes in three population-based cohorts;
a general population cohort and two chronic disease
cohorts composed of individuals diagnosed with diabetes
or osteoporosis.
Methods
Data sources
Administrative health data for this research were
obtained from the province of Saskatchewan, Canada
which has a population of approximately 1.1 million
[16]. Data on hospital contacts, physician contacts, and
outpatient prescriptions are collected and captured in
electronic databases that can be anonymously linked via
a unique personal health insurance number [17,18]. Like
all Canadian provinces, Saskatchewan has a provincial
health insurance plan that virtually all members of the
population are registered in except for a relatively small
proportion of the population (<1%) whose health care is
covered by the federal government (Royal Canadian
Mounted Police, veterans, and inmates in federal peni-
tentiaries). Additionally, First Nations people that have
treaty relationships with the federal government
(approximately 9% of the provincial population) also
receive some of their health benefits, including prescrip-
tion drug benefits, from the federal government. There-
fore these individuals are not included in the provincial
prescription drug benefit plan and related administrative
data files that were used in this study.
Hospital data is stored in the Discharge Abstract
Database. Diagnoses in hospital data are recorded using
the International Classification of Diseases, 9th Revision
(i.e., ICD-9) up to and including fiscal year 2001/02,
where a fiscal year extends from April 1 to March 31.
In fiscal year 2001/02, the International Classification of
Diseases, 10th revision, Canadian Version (i.e., ICD-10-
CA) was introduced and virtually all codes were
recorded in this format from fiscal year 2002/03 onward.
Between three and sixteen diagnoses are captured in
each record prior to the introduction of ICD-10-CA,
and up to 25 diagnoses are captured subsequently. The
type of diagnosis is also recorded, which identifies the
most responsible diagnosis for admission, comorbid
diagnoses that are not directly related to admission, and
diagnoses that developed after admission and which
represent the development of complications during the
hospitalization.
Data on physician services are contained in the
Medical Services Database. Physicians who are paid on
a fee-for-service basis submit billing claims to the pro-
vincial health ministry. A single diagnosis using three-
digit ICD-9 codes is recorded on each claim. Physicians
who are salaried are required to submit billing claims
for administrative purposes, a practice known as shadow
billing.
The Prescription Drug Database contains information
on all outpatient drugs dispensed to Saskatchewan resi-
dents who are eligible for coverage. Approximately 9%
of Saskatchewan residents - primarily Registered Indians
-a r en o te l i g i b l eb e c a u s et h e yh a v et h e i rp r e s c r i p t i o n
costs paid for by another government agency [18,19].
The database includes information on active ingredients,
strength and dosage form, date and quantity dispensed,
as well as the pharmacologic-therapeutic classification of
a drug based on the American Hospital Formulary Sys-
tem (AHFS) [20].
The Population Registry captures demographic charac-
teristics, location of residence, and dates of coverage by
the provincial health insurance plan. The Vital Statistics
Registry contains information on all births and deaths in
the province.
The accuracy and completeness of Saskatchewan’s
administrative databases have made them popular data
sources for numerous studies of population health and
health services utilization [21-23]. Ethical approval for
this research was received from the University of
Saskatchewan Biomedical Research Ethics Board.
Quail et al. BMC Health Services Research 2011, 11:146
http://www.biomedcentral.com/1472-6963/11/146
Page 2 of 12Cohort definitions
We used these administrative databases to define three
cohorts - a general population cohort and two chronic dis-
ease cohorts that are subsets of the general population
cohort - to investigate whether the performance of comor-
bidity measures varies among different study populations
and by outcome. In order to be included in one of these
cohorts, individuals must have had uninterrupted health
coverage in the year we assessed comorbidity (fiscal year
2001/02) and the year we assessed outcomes (fiscal year
2002/03). For the diabetes and osteoporosis cohorts, we
used data from April 1, 1996 to March 31, 2002 to identify
people with either of these conditions.
The general population cohort was composed of all
Saskatchewan residents aged 20 and older. We defined
the diabetes cohort using the National Diabetes Surveil-
lance System case definition [24], which has been devel-
oped using Canadian administrative data and validated
in previous research [25,26]. This case definition has
been shown to have excellent sensitivity (86%) and spe-
cificity (97%) [25]. It identifies all individuals who have a
diagnosis of diabetes (ICD-9: 250; ICD-10-CA: E10-E14)
in at least one hospital record or in at least two physi-
cian claims within a two-year period. The index date is
the earliest date of a diabetes diagnosis. We identified
all Saskatchewan residents 20 years of age and older
who met the case definition using data from April 1,
1996 to March 31, 2002.
We defined the osteoporosis cohort based upon the
results of a validation study that evaluated the sensitivity
and specificity of osteoporosis diagnosis codes in hospi-
tal and physician data, and outpatient prescription drug
records for an osteoprotective drug by comparing them
to bone mineral densitometry tests from a provincial
screening program [15]. The osteoporosis case definition
identifies all individuals aged 50 or older who have a
diagnosis of osteoporosis (ICD-9: 733; ICD-10-CA: M80,
M81) in at least one hospital record or at least one phy-
sician claim, or who have at least one outpatient drug
dispensation for an osteoprotective medication (i.e.,
alendronate, clodronate, etidronate, pamidronate, rise-
dronate, salmon calcitonin, raloxifene, teriparatide, zole-
dronic acid). The case definition has been shown to
have a sensitivity of 89.4% and a specificity of 91.5% in
women 50 years of age and older [27]. We assigned the
index date as the earliest date of diagnosis or prescrip-
tion drug dispensation. We identified all Saskatchewan
residents 50 years of age and older who met the case
definition using data from April 1, 1996 to March 31,
2002. Individuals were excluded if they had a diagnosis
for Paget’s disease (ICD-9: 731.0; ICD-10-CA: M88.0,
M88.8, M88.9) in the study period because they may
have different comorbidity characteristics than those
without the disease.
Comorbidity measures
Five comorbidity measures were considered: number of
different diagnoses, Charlson index, Elixhauser index,
number of different dispensed drugs, and the Chronic
Disease Score (CDS). Each measure was created using
data for fiscal year 2001/02.
The number of different diagnoses recorded to the
third digit in ICD-9 and ICD-10-CA was determined
using both the hospital and physician billing databases.
Any diagnoses related to pregnancy, childbirth, or abor-
tion were excluded because these events are not disease-
related.
T h eC h a r l s o ni n d e xi saw e i g h t e di n d e xo ft h eb u r -
den of comorbidity used to predict one-year mortality
[4]. It is calculated using diagnoses for 17 diseases
abstracted from hospital data. When present, each
condition is assigned a score from one to six and the
scores are summed to give a single value ranging from
0 to 32, where a higher score indicates a greater bur-
den of comorbidity. It was originally created using
ICD-9 codes but has been verified using ICD-10-CA
codes [28,29] as well as physician data [30]. We used
diagnoses codes from both hospital and physician data
to calculate the Charlson index using Quan et al’s
(2006) version [31,32]. For the hospital data, diagnoses
that developed after hospital admission and which
represent complications of the hospitalization were
excluded.
The Elixhauser index identifies the presence of 31
diseases using administrative data [5]. Each condition is
coded as present or absent and is entered into a statisti-
cal model as its own variable. Similar to the Charlson
index, the Elixhauser index was originally created using
ICD-9 codes but has since been verified using ICD-10-
CA codes [29]. We used diagnoses codes from both hos-
pital and physician data to calculate the Elixhauser index
using Quan et al’s (2006) version [33,34]. For the
hospital data, diagnoses that developed after hospital
admission and which represent complications of the
hospitalization were excluded.
The number of dispensed drugs was calculated using
the American Hospital Formulary Service (AHFS) phar-
macologic-therapeutic classification system by summing
the number of different four-digit drug classifications
for each cohort member to a maximum of 125. The
Chronic Disease Score (CDS) is also calculated based
upon the AHFS classification system [3]. Drugs used to
treat 17 conditions are identified and assigned a score
from one to five. The scores are summed to give a sin-
gle value ranging from 0 to 35, where a high score indi-
cates a greater burden of comorbidity. The CDS
predicts both hospitalization and mortality and is posi-
tively correlated with physician ratings of disease sever-
ity (r = 0.57) [3].
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Study outcomes included death and hospitalization
between April 1, 2002 and March 31, 2003. Death was
determined using data from the population registry, vital
statistics, and hospitalization databases. Two measures
of hospital use were examined: at least one hospitaliza-
tion and two or more hospitalizations. Hospitalizations
related to pregnancy, childbirth, and abortion were
excluded from the analysis. We investigated multiple
hospitalizations because hospitalization was a relatively
frequent occurrence in the chronic disease cohorts.
Other study variables
Other variables used to describe the cohorts include age,
sex, region of residence, and income quintile. All
demographic variables were determined for fiscal year
2001/02. Age and sex were identified from the Popula-
tion Registry. Region of residence and income were both
determined using a resident’s postal code identified
from the Population Registry. Income is a well known
factor that influences health outcomes, such that lower
income individuals are more likely to become ill,
disabled, and die than their more affluent counterparts
[35]. Region of residence may also affect health and the
use of health services. Nearly half of Saskatchewan
r e s i d e n t sl i v ei nar u r a la r e aa n dm a yf a c eb a r r i e r st o
accessing health care services that urban residents do
not. A resident was categorized as living in an urban
area if his/her postal code was in a Census Metropolitan
Area or Census Agglomeration with a population of
10,000 or more.
Income quintiles were calculated using a method
based on average household income from the 2001 Sta-
tistics Canada Census [36]. Each resident’sp o s t a lc o d e
w a si d e n t i f i e df r o mt h ePopulation Registry and linked
to a dissemination area, the smallest geographic unit
used in Census data. Residents were identified as
belonging to an income quintile based upon the Income
Per Person Equivalent which takes the size of a house-
hold into consideration. Income quintiles were calcu-
lated so that the entire population of Saskatchewan was
divided into five equal groups. Some residents could not
be assigned to a quintile because income measures are
suppressed for DAs with a small population. Approxi-
mately 14% of the total Saskatchewan population had a
missing income quintile. Imputed values were assigned
using a method that creates a predictive model for the
missing quintiles using sociodemographic variables that
are not suppressed such as marital status, ethnicity, and
employment status. A multiple imputation approach
was then used to assign income quintile [37]. After
applying this methodology, income could still not be
assigned to some rural areas in which approximately
one percent of Saskatchewan residents lived in fiscal
year 2001/02.
Statistical analysis
In order to ensure comparability with the general popu-
lation, we restricted both chronic disease cohorts to
individuals who were alive on April 1, 2002, and who
had uninterrupted health coverage for fiscal years 2001/
02 and 2002/03. Two sets of analyses were conducted;
one including all members of each cohort and the other
including only those cohort members age 65 and older.
Frequencies, means, and standard deviations were
used to describe the characteristics of each cohort. The
chronic disease cohorts are subsets of the general popu-
lation cohort and so McNemar’s test was used to test
for differences between the cohorts on each of the three
outcome measures. Validation of each comorbidity mea-
sure was conducted using multiple logistic regression
analysis [15]. Specifically, to assess the predictive perfor-
mance of each comorbidity measure a series of models
were fit to the data for each outcome. The base model
was comprised of the following variables: age (in years),
a quadratic age effect, sex, region of residence, and
income quintile. Five full models were then fit to the
data. Each model contained all of the variables in the
base model in addition to one or more variables defin-
ing the comorbidity measure. All comorbidity measures
were entered into the full models as continuous vari-
ables with the exception of the Elixhauser index, which
was included as a series of dichotomous variables. Sensi-
tivity analyses revealed that redefining the continuous
comorbidity measures as categorical variables did not
result in any substantial change in model fit as judged
by the Hosmer-Lemeshow goodness-of-fit test.
Discriminative performance for the base and full mod-
els was assessed using the c-statistic, which is equivalent
to the area under the receiver operating characteristic
(ROC) curve for dichotomous outcomes [27,38]. The c-
s t a t i s t i cr a n g e sf r o mz e r ot oo n e ,w i t hav a l u eo fo n e
representing perfect prediction and a value of 0.5 repre-
senting chance prediction. A value between 0.7 and 0.8
is considered to demonstrate acceptable predictive per-
formance, while a value greater than 0.8 demonstrates
excellent discriminative performance. The 95% confi-
dence intervals (CIs) were computed. Differences in the
c-statistic (i.e., Δc) for the base and full models were
tested using the method of DeLong et al. [39]. The per-
centage change in the c-statistic was also computed.
Model calibration was assessed using the Brier score,
which ranges from zero to one [28]. A lower score indi-
cates less prediction error. Given that a score of 0.25
can be achieved by assigning an event probability of 0.5
to each individual [28], a value less than 0.25 was
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standard deviation of the Brier score was also computed.
Analyses were conducted for each full cohort and then
for the age-restricted (65+) cohort using SAS software
[40].
Results
Table 1 contains summary data for the demographic
and socioeconomic variables, health outcomes, and
comorbidity measures for each cohort. We describe first
the findings for the full cohorts. We identified 662,423
individuals in the general population cohort, 41,925
individuals age in the diabetes cohort, and 28,028 indivi-
duals in the osteoporosis cohort. A total of 2,909 indivi-
duals were members of both the diabetes cohort (6.9%)
and osteoporosis cohort (10.4%). The general population
cohort was, on average, younger than the diabetes
cohort [mean age (SD) 47.9(17.9) versus 62.4(15.0)].
Females represented approximately 50% of both the
general population and diabetes cohort and the majority
of the osteoporosis cohort (86.1%). A greater proportion
of members of the diabetes cohort had incomes in the
lowest quintile (26.1%) than both the general population
and osteoporosis cohorts. The majority of individuals
lived in an urban setting, ranging from 52% in the dia-
betes cohort to 58% in both the general population and
osteoporosis cohort.
All three outcomes occurred less frequently in the
general population cohort than in either of the other
two cohorts. Each outcome was two to three times
more common in the diabetes and osteoporosis cohorts.
These differences were statistically significant for both
hospitalization outcomes but not for death.
For each comorbidity measure, the general population
cohort had the lowest mean score. The osteoporosis
cohort had the highest mean number of diagnoses while
the diabetes cohort had the highest mean number of
drugs and chronic disease score. Mean Charlson index
summary scores were identical in the osteoporosis and
diabetes cohorts. The Charlson value is less than one in
these disease-based cohorts because the cohorts were
created using diagnosis codes recorded over a 6-year
period, whereas the comorbidity measures were created
using diagnosis codes recorded within a single year.
Table 2 summarizes the distribution of Elixhauser cate-
gories. In each full cohort, uncomplicated hypertension
Table 1 Description of general population, diabetes, and osteoporosis full and age-restricted cohorts
General Population Diabetes Osteoporosis
Variable Full
(n = 662,423)
65+ years
(n = 137,700)
Full
(n = 41,925)
65+ years
(n = 20,025)
Full
(n = 28,068)
65+ years
(n = 20,090)
DEMOGRAPHICS
Age, mean (SD) 47.9 (17.9) 75.3 (7.3) 62.4 (15.0) 75.2 (6.9) 71.6 (10.8) 77.0 (7.4)
Female, % 51.3 56.8 47.8 49.7 86.1 87.1
Urban residence, % 58.2 51.1 51.8 49.5 58.0 56.8
Missing 0.2 0.1 0.1 0.1 0.1 0.1
Income quintile, %
Q1 (lowest) 21.6 22.2 26.1 24.7 22.2 23.3
Q2 22.0 23.6 23.0 23.6 22.3 22.7
Q3 18.2 18.7 17.0 18.3 18.7 19.2
Q4 16.6 15.8 14.8 15.0 17.0 16.5
Q5 (highest) 20.4 18.4 17.9 17.2 18.9 17.5
Missing 1.2 1.3 1.2 1.3 1.0 0.8
OUTCOMES
Death, % 1.3 5.1 4.3 7.5 4.7 6.1
One or more hospitalizations, % 17.4 31.8 31.9 39.9 33.9 37.2
Two or more hospitalizations, % 5.1 12.6 13.2 17.9 14.8 16.9
COMORBIDITY MEASURES
# Diagnoses,
mean (SD)
3.9 (4.4) 6.3 (5.6) 7.5 (6.4) 8.4 (6.7) 8.0 (6.2) 8.5 (6.4)
Charlson index
summary score, mean (SD)
0.3 (0.9) 0.7 (1.5) 0.8 (1.5) 1.1 (1.8) 0.8 (1.5) 0.9 (1.5)
# Drugs, mean (SD) 1.8 (1.0) 2.5 (1.2) 5.1 (3.9) 6.1 (3.9) 4.1 (2.4) 4.4 (2.4)
CDS, mean (SD) 1.4 (2.6) 3.3 (3.4) 4.8 (3.8) 5.6 (3.7) 3.6 (3.6) 4.0 (3.6)
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chronic pulmonary disease. Few members of the general
population had congestive heart failure (2.0%) although it
was the third and fourth most common chronic condi-
tion in the diabetes cohort (8.0%) and osteoporosis
cohort (8.2%), respectively. The prevalence of each
chronic condition was lowesti nt h eg e n e r a lp o p u l a t i o n
cohort for all Elixhauser categories. Compared to the
other cohorts, members of the diabetes cohort were
more likely to be identified as having complicated dia-
betes (14.7%) and renal failure (3.1%), while members of
the osteoporosis cohort were more likely to be identified
as having hypothyroidism (9.0%), depression (7.5%), and
rheumatic disease (6.9%).
When we restricted attention to only those cohort
members who were 65+ years, we found the general
population and diabetes cohorts were similar in terms of
age and urban residence, while the osteoporosis cohort
was slightly older and composed of more women (Table
1). While mean scores for all comorbidity measures
increased, the pattern across the age-restricted cohorts
was similar to that for the full cohorts.
Table 3 reports the results of the multivariable ana-
lyses for the full and age-restricted general population
Table 2 Elixhauser Index categories for the general population, diabetes, and osteoporosis full and age-restricted
cohorts, 2001/02
General Population Diabetes Osteoporosis
Variable Full
(%)
65+ years
(%)
Full
(%)
65+ years
(%)
Full
(%)
65+ years
(%)
Hypertension, uncomplicated 16.7 42.5 42.7 51.1 39.9 44.8
Chronic pulmonary disease 8.4 12.7 13.5 14.3 15.2 15.9
Depression 5.6 4.6 6.0 4.8 7.5 7.1
Hypothyroidism 3.4 6.6 4.7 5.6 9.0 9.4
Solid tumor 2.5 7.6 5.4 8.8 6.7 7.3
Congestive heart failure 2.0 8.1 8.0 13.4 8.2 10.7
Psychiatric disorder 1.3 4.1 2.7 4.4 4.3 5.6
Rheumatic disease 1.2 2.4 1.9 2.2 6.9 7.0
Diabetes, complicated 1.0 2.8 14.7 18.5 2.3 2.6
Valvular disease 1.0 2.6 2.2 3.1 2.8 3.3
Other neurological disorders 1.0 1.3 1.2 1.3 1.8 1.7
Cardiac arrhythmias 0.8 3.2 2.8 4.7 3.0 3.9
Fluid and electrolyte disorders 0.8 2.5 2.7 4.0 3.2 4.1
Coagulopathies 0.8 2.8 2.5 3.9 2.9 3.6
Metastatic cancer 0.8 2.4 1.7 2.8 2.4 2.6
Renal failure 0.6 1.8 3.1 4.2 1.9 2.3
Drug abuse 0.5 0.1 0.4 0.1 0.2 0.1
Peripheral vascular disease 0.4 1.3 1.5 2.2 1.2 1.5
Deficiency anemia 0.4 1.0 0.8 1.3 1.3 1.5
Hypertension, complicated 0.3 0.9 1.0 1.5 1.0 1.2
Pulmonary circulation disorders 0.3 1.0 0.8 1.2 1.2 1.4
Liver disease 0.3 0.3 0.7 0.6 0.5 0.4
Alcohol abuse 0.3 0.2 0.7 0.4 0.2 0.2
Diabetes, uncomplicated 0.2 0.5 3.0 3.3 0.4 0.4
Obesity 0.2 0.3 1.0 0.9 0.3 0.3
Paraplegia 0.2 0.3 0.4 0.6 0.3 0.3
Peptic ulcer disease 0.1 0.4 0.4 0.5 0.4 0.5
Lymphoma 0.1 0.2 0.2 0.3 0.3 0.3
Weight loss 0.1 0.2 0.2 0.2 0.3 0.3
Blood loss anemia <0.1 0.1 0.1 0.1 0.1 0.1
AIDS <0.1 <0.1 <0.1 0 0 0
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had a c-statistic of 0.880 (95% CI: 0.886, 0.892) and a
Brier score of 0.012, indicating excellent discrimination
and very low prediction error. The addition of a
comorbidity measure to the base model yielded a sta-
tistically significant improvement in the c-statistic for
all five measures, although the amount of change was
small (< 4%). The addition of the Elixhauser index to
the base model was associated with the largest c-
statistic (c = 0.913; 95% CI: 0.910, 0.916), followed by
the Charlson index (c = 0.905; 95% CI: 0.902, 0.908).
Hospitalization base models had markedly lower c-
statistics than the mortality base model. In fact, the
c-statistic for the base model for any hospitalization in
the full cohort failed to exceed the threshold of 0.70
and barely surpassed it for multiple hospitalizations
Table 3 Model comparisons for mortality and hospitalization in the general population cohort, full and age-restricted
Model Full cohort (n = 662,423) Age 65+ (n = 137,700)
c-statistic
(95% CI)
Brier
score (SD)
Δc (%) c-statistic
(95% CI)
Brier
score (SD)
Δ c (%)
Death
Base model 0.880
(0.877, 0.884)
0.012 (0.098) – 0.729
(0.723, 0.735)
0.046
(0.183)
–
+ # diagnoses 0.901
(0.898, 0.904)
0.012 (0.096) 0.021 (2.36) 0.769
(0.764, 0.775)
0.046
(0.179)
0.040 (5.53)
+ Charlson 0.905
(0.902, 0.908)
0.012 (0.095) 0.025 (2.81) 0.785
(0.779, 0.790)
0.045
(0.177)
0.056 (7.64)
+ Elixhauser 0.913
(0.910, 0.916)
0.012 (0.093) 0.033 (3.73) 0.805
(0.799, 0.810)
0.044
(0.173)
0.076 (10.36)
+ # drugs 0.894
(0.890, 0.897)
0.012 (0.096) 0.013 (1.53) 0.764
(0.759, 0.770)
0.045
(0.178)
0.035 (4.83)
+ CDS 0.889
(0.886, 0.892)
0.012 (0.097) 0.009 (1.01) 0.751
(0.745, 0.757)
0.046
(0.181)
0.022 (3.00)
One or more hospitalizations
Base model 0.652
(0.651, 0.654)
0.138 (0.238) – 0.563
(0.559, 0.566)
0.215
(0.171)
–
+ # diagnoses 0.722
(0.720, 0.724)
0.130 (0.233) 0.070 (10.68) 0.668
(0.664, 0.671)
0.202
(0.189)
0.105 (18.60)
+ Charlson 0.671
(0.669, 0.672)
0.136 (0.238) 0.018 (2.81) 0.613
(0.610, 0.616)
0.210
(0.179)
0.050 (8.92)
+ Elixhauser 0.682
(0.680, 0.683)
0.134 (0.236) 0.029 (4.47) 0.630
(0.627, 0.633)
0.206
(0.184)
0.067 (11.92)
+ # drugs 0.688
(0.686, 0.690)
0.134 (0.235) 0.036 (5.46) 0.625
(0.622, 0.628)
0.207
(0.181)
0.063 (11.10)
+ CDS 0.672
(0.671, 0.674)
0.136 (0.236) 0.020 (3.05) 0.604
(0.601, 0.607)
0.210
(0.177)
0.041 (7.34)
Two or more hospitalizations
Base model 0.706
(0.704, 0.709)
0.047 (0.187) – 0.571
(0.567, 0.576)
0.110
(0.246)
–
+ # diagnoses 0.782
(0.779, 0.785)
0.045 (0.179) 0.075 (10.67) 0.686
(0.682, 0.690)
0.105
(0.235)
0.115 (20.07)
+ Charlson 0.731
(0.728, 0.734)
0.047 (0.184) 0.024 (3.42) 0.633
(0.629, 0.638)
0.108
(0.241)
0.062 (10.92)
+ Elixhauser 0.748
(0.745, 0.751)
0.046 (0.181) 0.042 (5.91) 0.653
(0.649, 0.658)
0.106
(0.237)
0.082 (14.40)
+ # drugs 0.744
(0.742, 0.747)
0.046 (0.182) 0.038 (5.37) 0.638
(0.633, 0.642)
0.107
(0.238)
0.067 (11.66)
+ CDS 0.729
(0.726, 0.732)
0.047 (0.184) 0.023 (3.18) 0.619
(0.614, 0.623)
0.108
(0.241)
0.048 (8.32)
Base model includes age, age
2, sex, income quintile, and geography
CDS = Chronic Disease Score
Δc = difference in the c-statistic between the base and full models; c-statistics in boldface font are significantly different from the c-statistic for the base model,
according to the method of DeLong et al. [39]
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Page 7 of 12(c = 0.706; 95% CI: 0.704, 0.709). For each model, the
addition of every comorbidity measure was associated
with a statistically significant increase in the c-statistic.
The number of diagnoses was the best-performing
comorbidity measure for the models of one or more
hospitalizations (c = 0.722; 95% CI: 0.720, 0.724) and
two or more hospitalizations (c = 0.782; 95% CI: 0.779,
0.785).
Table 4 provides the multivariable models for the full
and age-restricted diabetes cohorts. Similar to the gen-
eral population cohort, the base model for death had
the largest c-statistic in the full cohort (c = 0.781; 95%
CI: 0.770, 0.791). The addition of each comorbidity mea-
sure to the base model resulted in a significant improve-
ment in the c-statistic. The greatest improvement was
observed for the Elixhauser index (c = 0.845; 95% CI:
Table 4 Model comparisons for mortality and hospitalization for diabetes cohort, full and age-restricted
Model Full cohort (n = 41,925) Age 65+ (n = 20,025)
c-statistic
(95% CI)
Brier
score (SD)
Δ c (%) c-statistic
(95% CI)
Brier
score (SD)
Δ c (%)
Death
Base model 0.781
(0.770, 0.791)
0.038
(0.166)
– 0.695
(0.680, 0.709)
0.067
(0.209)
–
+ # diagnoses 0.818
(0.809, 0.828)
0.037
(0.161)
0.037 (4.78) 0.749
(0.736, 0.762)
0.065
(0.202)
0.054 (7.81)
+ Charlson 0.830
(0.821, 0.839)
0.037
(0.161)
0.049 (6.33) 0.764
(0.752, 0.776)
0.065
(0.202)
0.070 (10.02)
+ Elixhauser 0.845
(0.836, 0.854)
0.036
(0.156)
0.064 (8.20) 0.788
(0.776, 0.800)
0.063
(0.196)
0.094 (13.50)
+ # drugs 0.799
(0.789, 0.810)
0.038
(0.163)
0.018 (2.36) 0.729
(0.715, 0.742)
0.065
(0.204)
0.034 (4.92)
+ CDS 0.789
(0.779, 0.800)
0.038
(0.165)
0.009 (1.11) 0.709
(0.695, 0.723)
0.066
(0.207)
0.014 (2.07)
One or more hospitalizations
Base model 0.610
(0.604, 0.616)
0.211
(0.174)
– 0.547
(0.539, 0.556)
0.238
(0.104)
–
+ # diagnoses 0.701
(0.695, 0.706)
0.195
(0.194)
0.091 (14.90) 0.655
(0.647, 0.663)
0.224
(0.148)
0.108 (19.63)
+ Charlson 0.666
(0.660, 0.672)
0.203
(0.187)
0.056 (9.21) 0.621
(0.613, 0.629)
0.231
(0.130)
0.074 (13.45)
+ Elixhauser 0.677
(0.671, 0.682)
0.198
(0.192)
0.067 (10.98) 0.634
(0.626, 0.642)
0.226
(0.143)
0.086 (15.76)
+ # drugs 0.641
(0.635, 0.647)
0.206
(0.181)
0.031 (5.11) 0.604
(0.596, 0.612)
0.232
(0.125)
0.056 (10.28)
+ CDS 0.624
(0.618, 0.630)
0.208
(0.177)
0.014 (2.31) 0.578
(0.570, 0.587)
0.235
(0.115)
0.031 (5.65)
Two or more hospitalizations
Base model 0.617
(0.609, 0.625)
0.113
(0.242)
– 0.546
(0.535, 0.556)
0.146
(0.245)
–
+ # diagnoses 0.726
(0.719, 0.733)
0.106
(0.230)
0.109 (17.61) 0.674
(0.665, 0.684)
0.139
(0.237)
0.129 (23.55)
+ Charlson 0.694
(0.687, 0.702)
0.110
(0.236)
0.077 (12.55) 0.643
(0.633, 0.653)
0.143
(0.240)
0.097 (17.76)
+ Elixhauser 0.709
(0.702, 0.717)
0.107
(0.232)
0.092 (14.96) 0.655
(0.645, 0.665)
0.139
(0.237)
0.109 (20.02)
+ # drugs 0.651
(0.643, 0.658)
0.111
(0.237)
0.034 (5.45) 0.603
(0.592, 0.614)
0.144
(0.241)
0.057 (10.49)
+ CDS 0.633
(0.625, 0.641)
0.112
(0.240)
0.016 (2.63) 0.580 (0.569, 0.590) 0.145
(0.242)
0.034 (6.22)
Base model includes age, age
2, sex, income quintile, and geography
CDS = Chronic Disease Score
Δc = difference in the c-statistic between the base and full models; c-statistics in boldface font are significantly different from the c-statistic for the base model,
according to the method of DeLong et al. [39]
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Page 8 of 120.836, 0.854), followed by the Charlson index (c = 0.830;
9 5 %C I :0 . 8 2 1 ,0 . 8 3 9 ) .C - s t a t istics for the base models
predicting hospitalization were below 0.70, and although
the addition of each comorbidity measure resulted in a
statistically significant improvement in the c-statistic,
few models exceeded the threshold of 0.70. The number
of diagnoses was associated with largest c-statistic for at
least one hospitalization (c- = 0.701; 95%CI: 0.695,
0.672) and two or more hospitalizations (c = 0.726; 95%
CI: 0.719, 0.733). Overall, there was better predictive
p e r f o r m a n c ei nt h eg e n e r a lc o h o r tt h a ni nt h ed i a b e t e s
cohort for all outcomes.
Table 5 reports the results of the multivariable models
for the full and age-restricted osteoporosis cohorts. The
base model for death had the largest c-statistic (c =
0.758; 95% CI: 0.745, 0.771). The addition of each
comorbidity measure to the base model was associated
with a statistically significant improvement in the
Table 5 Model comparisons for mortality and hospitalization for osteoporosis cohort, full and age-restricted
Model Full cohort (n = 28,068) Age 65+ (n = 20,090)
c-statistic
(95% CI)
Brier
score (SD)
Δ c (%) c-statistic
(95% CI)
Brier
Score (SD)
Δ c (%)
Death
Base model 0.758
(0.745, 0.771)
0.042
(0.175)
– 0.718
(0.703, 0.733)
0.055
(0.196)
–
+ # diagnoses 0.792
(0.780, 0.804)
0.042
(0.171)
0.034 (4.48) 0.756
(0.742, 0.769)
0.054
(0.191)
0.038 (5.29)
+ Charlson 0.811
(0.800, 0.822)
0.042
(0.170)
0.053 (6.95) 0.772
(0.759, 0.785)
0.054
(0.190)
0.054 (7.57)
+ Elixhauser 0.827
(0.817, 0.838)
0.040
(0.166)
0.069 (9.09) 0.793
(0.780, 0.805)
0.052
(0.185)
0.075 (10.42)
+ # drugs 0.782
(0.769, 0.794)
0.042
(0.172)
0.024 (3.10) 0.746
(0.732, 0.760)
0.054
(0.191)
0.028 (3.91)
+ CDS 0.778
(0.766, 0.791)
0.042
(0.172)
0.020 (2.62) 0.741
(0.727, 0.754)
0.054
(0.192)
0.023 (3.15)
One or more hospitalizations
Base model 0.579
(0.572, 0.586)
0.220
(0.157)
– 0.550
(0.542, 0.558)
0.232
(0.129)
–
+ # diagnoses 0.667
(0.660, 0.673)
0.208
(0.178)
0.088 (15.14) 0.647
(0.639, 0.654)
0.220
(0.157)
0.097 (17.54)
+ Charlson 0.619
(0.612, 0.626)
0.216
(0.166)
0.040 (6.98) 0.598
(0.590, 0.606)
0.227
(0.141)
0.048 (8.73)
+ Elixhauser 0.637
(0.630, 0.644)
0.212
(0.173)
0.058 (10.08) 0.620
(0.612, 0.628)
0.223
(0.151)
0.070 (12.65)
+ # drugs 0.631
(0.624, 0.638)
0.213
(0.168)
0.052 (9.02) 0.609
(0.601, 0.618)
0.225
(0.144)
0.059 (10.80)
+ CDS 0.618
(0.611, 0.625)
0.215
(0.166)
0.039 (6.69) 0.597
(0.589, 0.605)
0.227
(0.141)
0.047 (8.61)
Two or more hospitalizations
Base model 0.606
(0.597, 0.615)
0.124
(0.243)
– 0.570
(0.559, 0.580)
0.139
(0.245)
–
+ # diagnoses 0.697
(0.688, 0.705)
0.118
(0.235)
0.090 (14.92) 0.669
(0.659, 0.679)
0.133
(0.238)
0.099 (17.37)
+ Charlson 0.650
(0.641, 0.659)
0.122
(0.240)
0.044 (7.19) 0.619
(0.609, 0.630)
0.137
(0.242)
0.050 (8.73)
+ Elixhauser 0.672
(0.663, 0.681)
0.119
(0.237)
0.066 (10.86) 0.645
(0.634, 0.655)
0.135
(0.239)
0.075 (13.15)
+ # drugs 0.656
(0.647, 0.665)
0.121
(0.237)
0.050 (8.28) 0.625
(0.615, 0.636)
0.136
(0.240)
0.056 (9.80)
+ CDS 0.651
(0.642, 0.660)
0.121
(0.238)
0.045 (7.41) 0.620
(0.610, 0.631)
0.137
(0.240)
0.051 (8.89)
Base model includes age, age
2, sex, income quintile, and geography
CDS = Chronic Disease Score
Δc = difference in the c-statistic between the base and full models; c-statistics in boldface font are significantly different from the c-statistic for the base model,
according to the method of DeLong et al. [39]
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Page 9 of 12c-statistic, although the amount of change was largest
for the Elixhauser index (c = 0.827: 95% CI: 0.817,
0.838), followed by the Charlson index (c = 0.811; 95%
CI: 0.800, 0.822). For both hospitalization outcomes, the
c-statistic of all models failed to exceed 0.70. The num-
ber of diagnoses was associated with the greatest
improvement in the c-statistic for at least one hospitali-
zation (c-= 0.667; 95% CI: 0.660, 0.673) as well as for
two or more hospitalizations (c = 0.688; 95% CI: 0.688,
0.705). Overall, there was better predictive performance
in the general cohort than in the diabetes cohort for all
outcomes.
Results for the age-restricted cohorts were similar to
the results for each full cohort. C-statistics were lower
and Brier scores were higher in all models in the age-
restricted cohort compared to their equivalent models
in full cohort, but the same comorbidity measures were
identified as having the greatest improvement in predic-
tive performance. Additionally, the change in the c-sta-
tistic was greater for each model in the age-restricted
cohort model than for the counterpart model in the full
cohort.
Discussion
This research comparing discrimination and prediction
error associated with comorbidity measures in three
population-based cohorts has the following key findings.
First, the optimal comorbidity measure depends upon
the outcome of interest. However, for each of the out-
comes, the best performing comorbidity measures was
consistent across populations with different disease
characteristics. Finally, compared to the full general
population cohort, models in the chronic disease and
age-restricted cohorts had poorer discriminative perfor-
mance of a base set of demographic and socioeconomic
variables, but the improvement in discriminative perfor-
mance associated with a comorbidity measure was con-
sistently larger.
We found that the best performing comorbidity mea-
sure depends upon the outcome of interest. The number
of different diagnoses in both hospital and physician
databases was the best predictor of hospitalization,
whereas the best predictors of death were the Elixhauser
and Charlson indices. Our findings for health services
utilization are similar to those of Farley et al., who
f o u n dt h a tn u m b e ro fd i a g n o s e sa n dn u m b e ro fd r u g s
performed better than the Elixhauser and Charlson
indices for predicting health care expenditures in a gen-
eral population [41]. However, Perkins et al. reported
that a simple count of medications was the best predic-
tor of health care costs in a population-based cohort of
community-dwelling older adults aged 60 and older [7].
Perkins et al. investigated many of the same comorbidity
measures that we did including count of diagnoses,
count of drugs, CDS, and the Charlson index using both
hospital and physician data. The discrepancy between
Perkins’ and our findings may be the result of differ-
ences in how the number of drugs was ascertained. Per-
kins et al. had a pharmacist divide drugs into detailed
subclasses whereas we used the AHFS to the fourth
digit, which is not as specific. Another possible explana-
tion is that although Perkins et al. included a count of
diagnoses as one of their comorbidity measures, the
researchers restricted the count to ten common chronic
conditions, whereas we identified all conditions based
on diagnoses codes recorded in hospital and physician
databases.
Our finding that the Elixhauser and Charlson indices
are the optimal predictors of one-year mortality is also
in keeping with other studies of different populations
including in-patient populations, community-dwelling
older adults, and hypertensive adults [7,9,12,42].
Furthermore, studies that directly compare the Elixhau-
ser to Charlson indices found, as we did, that the Elix-
hauser index performed better than the Charlson index
[6,43,44].
Our findings show that, although the optimal comor-
bidity measure varies by outcome, results are remarkably
consistent across study populations with different dis-
ease profiles. This consistency in the performance of
comorbidity measures predicting one-year mortality was
also observed by Stukenborg et al. (2001) in five in-
patient populations (acute myocardial infarction, conges-
tive heart failure, chronic obstructive pulmonary disease,
hypertension with complications, and acute cerebrovas-
cular disease), although they limited their investigation
to only the Elixhauser and Charlson indices. Similarly,
in 2004 Schneeweiss et al. compared the discriminative
performance of four versions of the Charlson index and
two versions of the CDS for predicting one-year mortal-
ity. They found the rank order for the best performing
comorbidity measures was identical in four cohorts of
community-dwelling adults age 64 and older - two with
cardiovascular disease and two without restrictions. Our
results confirm these findings, but further expand upon
their work by investigating additional comorbidity mea-
sures, investigating health services utilization as an out-
come, and including adults of all ages in the study
cohorts.
Although the rank ordering of comorbidity measures
in terms of discriminant performance was consistent
across our study populations, we found that perfor-
mance was poorer in the chronic disease cohorts. Com-
pared to identical models in the general population
cohort, models in the diabetes and osteoporosis cohorts
had poorer discriminative performance (i.e., lower c-sta-
tistic values) and higher prediction error (i.e., higher
Brier scores). This may be the result of not including
Quail et al. BMC Health Services Research 2011, 11:146
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as the recency of diagnoses or exposure to certain medi-
cations. We did not include them in order to make the
models directly comparable between study cohorts. Par-
ticularly for health services outcomes, for which the c-
statistic rarely surpassed the cutoff of 0.70, adding other
variables might improve the performance of these
models.
We also observed diminished performance in the age-
restricted cohorts compared to the full cohorts although
the magnitudes of change in the c-statistics were consis-
tently larger. The increase in the magnitudes of change
in the c-statistics may be explained by the fact that
advancing age is associated with the presence of multi-
ple chronic illnesses [45]. The high prevalence of
chronic disease would account for a greater proportion
of the variation observed in the age-restricted cohorts
compared to the full cohort and which would corre-
spond to a proportionately greater increase in the c-
statistic.
The strengths of this study include the use of popula-
tion-based administrative databases and our comprehen-
sive investigation of multiple comorbidity measures with
multiple outcomes in a variety of study populations.
Furthermore, the cohorts are population-based which
ensures good generalizability of our findings.
There are some limitations to our research. Misclassi-
fication bias for specific comorbid conditions may occur
as a result of inaccurate diagnosis coding in the admin-
istrative databases. Specifically, physicians may code a
suspected diagnosis only to rule it out later and which
would falsely inflate scores for diagnosis-based comor-
bidity measures. As well, comorbidity measures were
constructed using a single year of administrative data so
individuals that have a disease but did not have any
health service records containing a diagnosis of that dis-
ease during the one year timeframe would not be cap-
tured in the comorbidity measure for that disease. For
example, of the diabetes cohort identified for this study
- based on diagnosis codes occurring during a 6-year
period - only 15% had a diabetes diagnosis code occur-
ring during the one-year period upon which the Elix-
hauser index was based. We could have reduced the
likelihood for misclassification of the comorbidity mea-
sures by expanding the time-frame for ascertainment of
comorbidity to more than one year, but a one-year time
frame has been adopted in other studies [7-9] and
enables direct comparison with our results. Further-
more, a study comparing varying time frames for the
assessment of comorbidity in the prediction of one-year
mortality found that a longer time frame did not
improve the c-statistic substantially [46]. Another limita-
tion is that our finding that the best performing comor-
bidity measure is consistent across cohorts may be
because the chronic disease cohorts are subsets of the
general population cohort. This is unlikely though, given
that people with diabetes and/or osteoporosis comprise
only about 5% of the full general population cohort and
15% of the age 65+ general population cohort.
Conclusions
Based on the results of this research, the optimal
comorbidity measure is primarily dependent upon the
outcome of interest and not on the study population.
Overall, the count of diagnoses had the best predictive
performance for hospital utilization while the Elixhauser
index, followed by the Charlson index, had the best pre-
dictive performance for mortality. These findings were
consistent in a general population cohort and two
chronic disease cohorts, even when analyses were
restricted to older adults.
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